动脉介入化疗配合口服化疗治疗胰腺癌的疗效观察  

Clinical Effect of Artery Intervention Chems Matching Oral Chems Drugs in Pancreatic Cancer

作　　者：李威[1] 李大伟[1] 

机构地区：[1]黑龙江省医院介入科,黑龙江哈尔滨150036

出　　处：《黑龙江医学》2009年第7期523-525,共3页Heilongjiang Medical Journal

摘　　要：目的分析经动脉使用吉西他滨配合口服卡培他滨治疗中、晚期胰腺癌的近期疗效及安全性。方法对46例中晚期胰腺癌患者行经动脉灌注吉西他滨1000mg/m2,分别于第1、8d灌注;卡培他滨2500mg/m2,口服,2次/d,使用14d,21d为1个周期,2个周期后评定疗效。结果临床受益率(CBR)为71.8%(33/46),客观缓解率21.7%(10/46),中位生存期9.45个月,1年生存率13%(6/46),CA19-9治疗后平均下降32.4%。主要毒副反应为骨髓抑制及消化道反应。结论动脉介入吉西他滨配合口服卡培他滨治疗胰腺癌临床受益率高,有较好的客观缓解率,毒副反应较轻。Objective To investigate curative effect and safety of gemcitabine by intra arterial infusion chemotherapy. Methods Advanced pancreatic cancer were given gemcitabine 1 000 mg/m^2, administered on days l, 8 by arteria hepatica or superior mesenteric artery infusion. Capecitabine 2 500 mg/m^2, twice daily for 14 days, each cycle was 21 days, and clinical response was evaluated after 2 cycles. Results According to the standard of clinical benefie response （CBR）, 71.8 % （33/46） patients achieved the CBR. 10 cases reached objective remission, median suruival time is 9. 45 months. The main toxieties and side effeets were myelosuppression and digestive tract reaction. Conclusion The Combine treatment has high CBR rate and low toxicities and side effeces in the treatment of advanced pancreatic Caneer.

关 键 词：吉西他滨 卡培他滨 胰腺癌 

分 类 号：R815[医药卫生—放射医学]